Day One Biopharmaceuticals (NASDAQ:DAWN) Posts Quarterly Earnings Results, Misses Expectations By $0.34 EPS

Day One Biopharmaceuticals (NASDAQ:DAWN) posted its quarterly earnings data on Tuesday. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34), Zacks reports.

Day One Biopharmaceuticals Stock Down 3.0 %

NASDAQ DAWN opened at $11.82 on Wednesday. The firm has a market capitalization of $1.19 billion, a P/E ratio of -11.48 and a beta of -1.46. The company has a 50-day moving average price of $12.34 and a 200-day moving average price of $13.46. Day One Biopharmaceuticals has a 52 week low of $11.13 and a 52 week high of $18.07.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Needham & Company LLC restated a “buy” rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday. TD Cowen upgraded shares of Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th. Bank of America decreased their target price on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. The Goldman Sachs Group cut their price target on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating on the stock in a report on Monday, February 10th. Finally, HC Wainwright cut their target price on Day One Biopharmaceuticals from $40.00 to $36.00 and set a “buy” rating on the stock in a research note on Wednesday. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $35.00.

Insider Activity at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 4,646 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $55,566.16. Following the completion of the sale, the general counsel now owns 39,602 shares in the company, valued at $473,639.92. This represents a 10.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Samuel C. Blackman sold 30,000 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $13.31, for a total value of $399,300.00. Following the transaction, the insider now directly owns 1,034,015 shares in the company, valued at approximately $13,762,739.65. The trade was a 2.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 51,064 shares of company stock worth $651,225. 8.40% of the stock is owned by company insiders.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.